Community Investing Ideas

Global Weekly Picks

US$21.53
FV
60.2% undervalued intrinsic discount
7k
users have viewed this narrative
19users have liked this narrative
0users have commented on this narrative
137users have followed this narrative
US$42.3
FV
13.7% undervalued intrinsic discount
2.5k
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
US$989.24
FV
51.0% undervalued intrinsic discount
19.96%
Revenue growth p.a.
2.1k
users have viewed this narrative
1users have liked this narrative
2users have commented on this narrative
32users have followed this narrative
CRMD logo
CorMedix

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.Read more

View narrative
US$12
33.9% undervalued intrinsic discount
Fair Value
Revenue
38.8% p.a.
Profit Margin
51.99%
Future PE
3.42x
Price in 2031
US$16.82
US$274.31
63.9% overvalued intrinsic discount
Fair Value
Revenue
30% p.a.
Profit Margin
15%
Future PE
60x
Price in 2028
US$360.63
US$74.78
12.1% overvalued intrinsic discount
Fair Value
Revenue
25% p.a.
Profit Margin
10%
Future PE
35x
Price in 2031
US$112.03